Cybersecurity requirements, which are being debated in Brussels these months, could herald markedly higher encryption and cybersecurity expenses for many firms, including those in the life sciences industry, as evident in the European Commission's impact assessment of its revised cybersecurity directive proposal, the NIS2.
Were it only up to the Commission and members of the European Parliament, more companies – including, for instance, drugmakers – would face new rules pertaining to encryption and the reporting of cyberattacks, and more.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.